Brokerages forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report earnings of $0.53 per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The highest EPS estimate is $0.57 and the lowest is $0.45. Teva Pharmaceutical Industries posted earnings per share of $0.93 in the same quarter last year, which suggests a negative year over year growth rate of 43%. The business is expected to announce its next earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.80 per share for the current financial year, with EPS estimates ranging from $2.71 to $3.03. For the next year, analysts anticipate that the firm will post earnings of $2.83 per share, with EPS estimates ranging from $2.65 to $3.10. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.54 billion. During the same quarter in the previous year, the business posted $1.00 EPS. The company’s quarterly revenue was down 19.4% on a year-over-year basis.
TEVA has been the subject of several recent analyst reports. Goldman Sachs Group raised Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price target for the company in a research report on Monday, October 1st. Credit Suisse Group lowered Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $25.00 to $23.00 in a research report on Friday, September 7th. Leerink Swann raised Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and lifted their price target for the stock from $16.00 to $24.00 in a research report on Monday, October 1st. Cantor Fitzgerald set a $25.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, September 14th. Finally, Mizuho lifted their price target on Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Five equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $21.58.
In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Iris Beck Codner sold 4,165 shares of the business’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $22.70, for a total value of $94,545.50. Following the completion of the transaction, the executive vice president now directly owns 8,290 shares of the company’s stock, valued at approximately $188,183. The disclosure for this sale can be found here. In the last three months, insiders sold 10,350 shares of company stock valued at $239,430. 0.43% of the stock is owned by insiders.
Large investors have recently modified their holdings of the business. CWM LLC raised its position in Teva Pharmaceutical Industries by 315,000.0% in the 3rd quarter. CWM LLC now owns 6,302 shares of the company’s stock worth $136,000 after buying an additional 6,300 shares during the last quarter. Wealthstreet Investment Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $200,000. MAI Capital Management purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $204,000. Greenleaf Trust purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $215,000. Finally, Rehmann Capital Advisory Group increased its position in shares of Teva Pharmaceutical Industries by 136.2% during the 2nd quarter. Rehmann Capital Advisory Group now owns 9,019 shares of the company’s stock valued at $219,000 after purchasing an additional 5,201 shares during the last quarter. 65.10% of the stock is owned by institutional investors and hedge funds.
Shares of TEVA stock opened at $22.85 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. The firm has a market cap of $22.97 billion, a PE ratio of 5.81, a price-to-earnings-growth ratio of 1.85 and a beta of 0.77. Teva Pharmaceutical Industries has a 12 month low of $11.41 and a 12 month high of $25.96.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: How Do You Calculate Return on Investment (ROI)?
Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.